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Abstract
The activated AHR/ARNT complex (AHRC) regulates the expression of target genes upon exposure to environmental
contaminants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Importantly, evidence has shown that TCDD represses
estrogen receptor (ER) target gene activation through the AHRC. Our data indicates that AHR and ARNT act independently
from each other at non-dioxin response element sites. Therefore, we sought to determine the specific functions of AHR and
ARNT in estrogen-dependent signaling in human MCF7 breast cancer and human ECC-1 endometrial carcinoma cells.
Knockdown of AHR with siRNA abrogates dioxin-inducible repression of estrogen-dependent gene transcription.
Intriguingly, knockdown of ARNT does not effect TCDD-mediated repression of estrogen-regulated transcription,
suggesting that AHR represses ER function independently of ARNT. This theory is supported by the ability of the selective
AHR modulator 39,49-dimethoxy-a-naphthoflavone (DiMNF) to repress estrogen-inducible transcription. Furthermore, basal
and estrogen-activated transcription of the genes encoding cathepsin-D and pS2 are down-regulated in MCF7 cells but up-
regulated in ECC-1 cells in response to loss of ARNT. These responses are mirrored at the protein level with cathepsin-D.
Furthermore, knock-down of ARNT led to opposite but corresponding changes in estrogen-stimulated proliferation in both
MCF7 and ECC-1 cells. We have obtained experimental evidence demonstrating a dioxin-dependent repressor function for
AHR and a dioxin-independent co-activator/co-repressor function for ARNT in estrogen signalling. These results provide us
with further insight into the mechanisms of transcription factor crosstalk and putative therapeutic targets in estrogen-
positive cancers.
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Introduction
Elucidating the mechanisms underlying transcription is crucial
to our understanding of how cells and organisms respond to
physiological signals and environmental stimuli. The aryl hydro-
carbon receptor (AHR) and the aryl hydrocarbon receptor nuclear
translocator (ARNT) are members of the basic helix-loop-helix/
PER-ARNT-SIM (bHLH-PAS) family of proteins and form a
heterodimeric transcription factor upon binding a variety of
environmental contaminants, including 2,3,7,8-tetrachlorodiben-
zo-p-dioxin (TCDD) [1]. The activated AHR/ARNT complex
(AHRC) plays key roles in carcinogenesis and regulates the
expression of Cytochrome P4501A1 (CYP1A1) and other xenobiotic
target genes to combat the effects of environmental contaminants
[1]. In addition, AHR has been shown to be important for normal
development and physiological homeostasis [2,3,4] and is essential
for certain functions of the immune response, such as regulation of
interleukin-17 producing T-helper cells [5] and induction of the
cytokine interleukin-6 in MCF7 breast cancer cells [6].
Unliganded AHR exists in the cytoplasm as part of a multimeric
complex containing two molecules of HSP90, the HSP90 co-
chaperone p23, and hepatitis B virus X-associated protein 2
(XAP2) [7,8,9,10]. Upon ligand binding, AHR translocates to the
nucleus where it associates with ARNT to form a functional
transcription factor complex, the AHRC. As an activated
complex, the AHRC is capable of recruiting regulatory proteins,
such as steroid receptor coactivator-1 (SRC-1), CREB binding
protein (CBP/p300), NCoA2/GRIP1 [11,12], receptor-interact-
ing-protein 140 (RIP140) [13], CoCoA [14], GAC63 [15], NcoA4
[16] and TRIP230 [17], which play significant roles in
determining the activity of TCDD-induced gene transcription.
These co-activators and co-repressors incorporate themselves into
multimeric complexes that modify chromatin structure, stabilize
core transcriptional machinery, and mediate RNA chain elonga-
tion [18]. In addition to these classic transcriptional co-activators
and co-repressors, AHR is recruited by other transcription factors
during transcription, including estrogen receptor-a (ERa)
[11,19,20] and NF-kB [21] to modify their intrinsic activities.
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ERa/b are ligand activated transcription factors that belong to
the superfamily of nuclear hormone receptors (NR) [22] and bind
17b-estradiol (E2) to regulate genes involved in reproduction and
cellular growth and proliferation [23]. Upon ligand binding, ER
forms a functional homodimer and binds its cognate response
elements. Interestingly, there is a ligand-dependent reciprocal
disruption between ER and AHR signaling. For instance,
activated ERa inhibits AHRC activity at CYP1A1 through direct
protein-protein interactions, termed transrepression [11]. Conversely,
TCDD’s anti-estrogenic properties are well documented as it
represses the E2-inducible genes pS2 and cathepsin-D (CAT-D)
[24,25,26]. However, the mechanisms of repression occurring at
E2-responsive genes are unclear. Proposed theories for this
repression include: (i) competition for a common pool of co-
activators [27]; (ii) a direct down-regulation of CAT-D transcrip-
tion through upstream inhibitory dioxin response elements [28];
(iii) activation of a TCDD-inducible inhibitory factor [28]; (iv) an
AHR-dependent E3-ligase that degrades proteins crucial for ER-
signalling [29], or; (v) a direct transrepression interaction between
AHR and ER [11,19].
In this study, we examined the role of AHR and ARNT on
ERa-dependent target gene transcription in the human MCF7
breast cancer and the human ECC-1 endometrial-cervical cancer
cell lines. Our data suggest that AHR and ARNT act
independently from each other at off-target sites and we revealed
that ARNT is not essential for TCDD-dependent repression of
ER-signaling. In addition, we have demonstrated that ARNT acts
as a cell specific coactivator in MCF7 cells, and as a corepressor in
ECC-1 cells. Finally, we show that ARNT knockdown not only
affects accumulation of mRNA and protein of ERa-target genes,
but also has phenotypic consequences by influencing ERa-
mediated cell proliferation.
Results
AHR-dependent repression of estrogen signaling in ECC-
1 cells
The presence of AHR, ARNT and ERa at the dioxin-inducible
CYP1A1 enhancer and the E2-inducible pS2 promoter has already
been documented in MCF7 cells and other breast cancer cell lines
[11,19,20,30] . Although preliminary studies have identified ECC-
1 human endometrial cells as an ideal system to study dioxin
disruption of estrogen signaling [31,32] very little is known
concerning the roles of AHR, ARNT and ER and their respective
interactions in this cell line. We employed the ChIP assay to
ascertain the status of these proteins at the pS2 promoter and
CYP1A1 enhancer in both the presence and absence of E2 and
TCDD. ECC-1 cells were treated with DMSO, 10 nM E2, 2 nM
TCDD or a combination of E2 and TCDD for 45 min. After
chemically cross-linking protein to DNA with formaldehyde, cells
were harvested and sonicated. Sheared DNA-protein complexes
were precipitated with antibodies specific to AHR, ARNT or ERa
and then isolated complexes were reverse-crosslinked and DNA
was subjected to PCR amplification. Consistent with other
investigators’ observations in breast cancer cells, we observed the
recruitment of AHR and ARNT on the human CYP1A1 enhancer
in a TCDD-dependent fashion and ERa was greatly enriched only
after treatment with a combination of 2 nM TCDD and 10 nM
E2 (Figure 1A). Furthermore, the recruitment of ERa to the pS2
promoter occurs in an E2-dependent fashion while AHR and
ARNT are present after treatment with either ligand but are
enriched during co-treatment (Figure 1B).
We have previously shown that ERa associates with the AHRC
to mediate estradiol-dependent transrepression of dioxin-inducible
gene transcription [11]. Therefore, we set out to determine the
functional significance of AHR in estrogen-inducible gene
transcription. We transfected ECC-1 cells with small inhibitory
RNA directed towards either AHR (siAHR) or a GFP negative
control (siGFP). After transfection, cells were serum starved for
24 h, followed by 24 h ligand treatment and then harvested for
total mRNA that was quantified through quantitative PCR. As
expected, ablation of AHR and co-treatment with 2 nM TCDD
and 10 nM E2 results in the loss of TCDD-induced repression of
pS2 transcription (Figure 1C). However, loss of AHR had no
measurable effect on basal, or estrogen activated pS2 mRNA
accumulation. As a control for siRNA specificity, Western blots of
AHR protein show a greatly reduced expression of AHR protein
after transfection and unchanged protein levels of ERa and XAP2
which served as a loading control (Figure 1E). These demonstrate
the specificity of the siRNA’s to AHR, and that loss of AHR does
not affect accumulation or turnover of basal ERa protein levels.
Furthermore, the induction of CYP1A1 transcription with TCDD
after AHR knockdown is attenuated when compared to the siGFP
negative control (Figure 1D). Thus, AHR is a requirement for
TCDD-induced repression of E2-responsive gene transcription
and the increased transcriptional response with combinatorial
treatment is due solely to the loss of AHR and other putative
transcriptional modifiers associated with its presence. Finally, we
obtained essentially identical results in both MCF7 and ECC-1 cell
lines under serum-starved or charcoal-stripped serum conditions
suggesting that differences in the cell lines’ ability to go through
cell cycle does not impact this phenomenon. Together, these
results support the concept that the ECC-1 cell line is an excellent
alternative cell model to study dioxin-induced disruption of
estrogen receptor signaling.
ARNT has cell specific co-activator/co-repressor functions
The identification of ARNT as a co-activator in estrogen
signalling [27,30], juxtaposed with the known transrepressor
effects of TCDD, led us to investigate the role played by ARNT
in TCDD-mediated transrepression of ER function in various
human cancer cell lines, namely MCF7 and ECC-1 cells. Through
siRNA directed towards ARNT and a scrambled negative control
(siSCX), and subsequent qPCR analysis of endogenous pS2 and
CAT-D gene transcription, we made several interesting observa-
tions. First, ARNT displays co-repressor properties in ECC-1 cells.
Accumulation of pS2 (Figure 2A) and CAT-D (Figure 2B) mRNA
levels are exacerbated during E2 treatments after loss of ARNT
suggesting a cell specific function for ARNT independent of AHR.
Furthermore, we observed this phenomena with three separate
siRNAs directed towards ARNT (siRNA’s 1 and 3 are shown in
Figure 2A, B and C). We used at least two siRNA’s for all other
experimental parameters with essentially identical results, but for
brevity, hereafter we only present data depicting the use of one
siRNA. Secondly, consistent with the findings of several other
investigators, ARNT displayed co-activator properties in MCF7
cells [27,30]. Indeed, knockdown of ARNT protein dampens E2-
induced transcription of pS2 (Figure 2C) and CAT-D (Figure 2D).
Finally, in a dose response experiment, we observed a concomitant
decrease of CAT-D protein levels with increasing concentrations
of TCDD in both ECC-1 and MCF7 cells (Figure 2E). These data
indicate that ARNT function as it relates to ER signaling is likely
dictated by other factors specific to the cellular environment.
To determine if the modulation of transcriptional activity
translated into similar protein expression profiles, we used Western
blot analysis to visualize the level of CAT-D protein after ARNT
knockdown. Cells were transfected and ligand treated under
identical conditions as the qPCR parameters. When compared to
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the scrambled negative control, CAT-D protein expression after
E2 treatment is exacerbated in ECC-1 cells with ARNT
knockdown (Figure 3A). Conversely, MCF7 cells transfected with
ARNT siRNA resulted in a blunted expression of CAT-D protein
during E2 treatment (Figure 3C). Furthermore, ERa levels
remained consistent, regardless of ARNT status (Figure 3A and
C). Most importantly, dioxin-induced repression of ER signaling
was maintained at the protein level after ARNT knockdown
(Figure 3A and C). The representative blots were normalized to a-
tubulin and luminescence was measured using GeneTools 4.01.2
software (Syngene). These normalized values showed a two-fold
induction of CAT-D in ECC-1 cells with ARNT knockdown after
E2 treatment (Figure 3B, columns 2 and 6), whereas in MCF7
cells, knock-down of ARNT resulted in a 40% decrease in E2-
dependent CAT-D expression (Figure 3D, colunms 2 and 6).
These results provide concrete evidence that the level of protein
Figure 1. AHR is required for TCDD-mediated repression of E2-induced gene transcription. Chromatin immunoprecipitation assays of the
CYP1A1 enhancer (A) and pS2 promoter (B) regions in ECC-1 cells using antibodies targeting AHR, ARNT or ERa. Cells were treated for 45 min with
either DMSO, E2 (10 nM), TCDD (2 nM) or a combination of E2 and TCDD. (C and D) The functional role of AHR in TCDD-mediated transcription. ECC-
1 cells were transfected with siRNAs to either GFP (siGFP) as a negative control or AHR (siAHR#3 or siAHR#4) 24 h prior to ligand treatment, then
cells were treated with DMSO, E2 (10 nM), TCDD (2 nM) or a combination of E2 and TCDD. The mRNA levels for pS2 (C) and CYP1A1 (D) were
determined through real-time RT-PCR and normalized to constitutively active GAPDH expression. (E) ECC-1 cells were transfected with siRNA’s to AHR
and harvested for whole cell lysates for Western Blot analysis of AHR, ERa and XAP2 protein levels.
doi:10.1371/journal.pone.0029545.g001
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Figure 2. Loss of ARNT shows a cell specific co-activator or co-repressor transcriptional function. ECC-1 cells (A and B) and MCF7 cells
(C and D) were transfected with either scrambled siRNA (siSCX) or siRNA directed to ARNT (siARNT#1 or siARNT#3). Twenty-four hours after
transfection, cells were treated with vehicle (DMSO), E2 (10 nM), TCDD (2 nM) or a combination of E2 and TCDD. Gene expression was determined by
Role of AHR and ARNT in Estrogen Signalling
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expression mirrors the transcriptional response in both cell lines
and that physiological consequences must ensue with loss of
ARNT.
These surprising results were coupled with the observation that
TCDD-induced repression of ER-signaling is maintained in both
cell lines after ARNT knockdown (Figure 2 and 3) thus providing
evidence that ARNT is not required for TCDD/AHR-dependent
repression of ERa signaling. This hypothesis is supported by the
ability of a selective aryl hydrocarbon receptor modulator
(SAHRM) to repress estrogen signaling. We examined the ability
of the known SAHRM, DiMNF [33,34] to repress E2-mediated
transcription by RT-PCR in MCF7 and ECC-1 cells (Figure 4).
DiMNF was as effective at repressing CAT-D mRNA accumu-
lation as TCDD. DiMNF is a potent antagonist of AHR and
Figure 3. Effect of ARNT knockdown on ARNT, CAT-D and ERa protein levels. ECC-1 (A and B) and MCF7 (C and D) cells were transfected
with either siSCX or siARNT and ligand treated as described in Figure 2. (A and C) Representative Western blots of ARNT, CAT-D, ERa and a-tubulin
protein levels. Bar graphs of CAT-D protein levels in ECC-1 (B) and MCF7 (D) cells after normalizing luminescence values to a-tubulin. Open bars
represent ligand treatments after siRNA to scrambled negative control (siSCX) and closed (black) bars represent ligand treatments after siRNA to
ARNT (siARNT). Experiments were performed three times with essentially identical outcomes.
doi:10.1371/journal.pone.0029545.g003
real-time RT-PCR after isolation and reverse transcription of total RNA. CAT-D and pS2 expression were normalized to constitutively active 36B4 gene
expression. (E) Western blot analysis of CAT-D protein levels in MCF7 and ECC-1 cells. Cells were treated with DMSO or E2 (10 nM) and varying
concentrations of TCDD (10 pM, 50 pM, 100 pM, 500 pM, 1 nM or 5 nM). After 24 hours of treatment, whole cell lysates were harvested, and Western
Blot assays were performed using antibodies directed against CAT-D and a-tubulin. Error bars represent 6 S.D. * p,0.05.
doi:10.1371/journal.pone.0029545.g002
Role of AHR and ARNT in Estrogen Signalling
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29545
effectively displaces TCDD from the receptor at 1 mM [34]. In
addition, DiMNF fails to induce AHR-ARNT-dioxin response
element formation in an electrophoretic mobility shift assay,
suggesting that AHR-ARNT dimerization may not occur [34],
thus, it seems likely that AHR’s transrepression function is entirely
ARNT-independent.
ARNT knockdown causes increased proliferation in ECC-1
cells and decreased proliferation in MCF7 cells
Sensitivity to estrogen has been linked to proliferation and cell
transformation in ER-positive carcinoma cells [35]. To establish if
ARNT can influence E2-dependent cellular proliferation, we
performed proliferation assays on ECC-1 and MCF7 cells after
ARNT siRNA treatment. Consistent with our quantitative PCR
and Western blot data, ECC1 and MCF7 cells displayed altered
rates of proliferation after ARNT knockdown compared to cells
transfected with the scrambled negative control siRNA (Figure 5A
and B). Knockdown of ARNT was monitored for 72 h and the
significant knock-down observed was unchanged essentially at
each time point (Figure 5C). Neither cell line displayed altered
growth patterns until the 48 hour time point. At 48 hours, ECC-1
cells in both the siSCX and siARNT conditions showed modest
proliferation in response to E2 treatments. At the 96 hour time
point, there was a highly significant increase in E2-inducible
proliferation of ECC-1 cells treated with siARNT, compared to
scrambled control treated cells. Intriguingly, ARNT knockdown
increased basal growth rates and caused an exacerbated response
to E2 with the cell number nearly doubling in the siARNT E2
treatments compared to the siSCX E2 treatments. Conversely,
MCF7 cells showed a decreased proliferation rate after ARNT
knockdown (Figure 5B). The growth rates were not significantly
different until the 48 h time point, when the E2-inducible
proliferative response in the scrambled negative control was
apparent. The siARNT transfected cells had a blunted growth
response during both control and E2 conditions. At 96 hours, the
cells began losing sensitivity to E2 and entered into a senescent
state. Whether or not this was due to the growth conditions is
unclear. However, these data further support the hypothesis that
ARNT has co-repressor properties in ECC-1 cells and co-activator
properties in MCF7 cells. Moreover, the sensitivity to E2 and the
reciprocal growth responses exhibited by the two cell lines are
bona fide phenotypic consequences of ARNT ablation.
Discussion
Many environmental contaminants that serve as activators of
the aryl hydrocarbon receptor are known as putative endocrine
disrupting compounds. Exposure to many of these compounds
occur on a daily basis and represents significant risks to human
health. In particular, the repressive effects elicited by ligands of the
AHR on ER signaling have been well documented [11,19,
36,37,38]. Other reports have described the co-activator potential
of ARNT for ER-mediated transcription [27]. Despite the growing
body of evidence to support roles for AHR and ARNT in ER
function, little is known about the normal physiological role of
these proteins as they relate to estrogen signaling or the molecular
determinants of toxicant-induced transrepression of ER function
by AHR. Finally, this investigation revealed that ARNT is not
essential for AHR-mediated off-target transrepression. In order to
delineate the molecular mechanisms underlying AHR-mediated
transrepression we sought to uncouple AHR and ARNT function
in ER-positive human cancer cell lines. In doing so, we discovered
that ARNT attenuates activated ER-target gene transcription in
ECC-1 cells, in direct contrast to its co-activator function
described in MCF7 cells [27].
ARNT was originally identified as a bona fide transcription
factor [39] and dimerization partner of AHR [40]. Beyond its
canonical transcription factor function, ARNT can interact with
several other transcription factors, including ERa [11] and its co-
activator function for ER signaling has been well described
[27,30]. Therefore, we expected that knockdown of ARNT in
ECC-1 endometrial-cervical cancer cells would result in a
diminution of ER target gene expression. The resulting increase
in mRNA accumulation, protein expression and E2-inducible
proliferation strongly suggests that ARNT acts as a transcriptional
co-repressor in this cell line. The molecular mechanism(s)
underlying the differences observed in MCF7 and ECC-1 cells
likely is related to differences in the nature and composition of the
ancillary transcriptional machinery recruited by ARNT in each
cell line. ARNT presents several different protein-protein
Figure 4. Effect of selective aryl hydrocarbon receptor
modulators on estrogen-inducible transcription. The effect of
1 mM DiMNF on E2-inducible CAT-D expression in MCF7 and ECC-1 cells.
Cells were treated with the indicated ligands for 24 h prior to RNA
isolation. Gene expression was determined as described above. Error
bars represent 6 S.D. * p,0.05.
doi:10.1371/journal.pone.0029545.g004
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interaction domains for the recruitment of co-activator proteins,
including a carboxy-terminal transactivation domain [18], its PAS-
B region [41] and its basic-helix-loop-helix domain [12]. In
addition, an association between ARNT and the transcriptional
co-repressor protein, SMRT has been demonstrated [42]. Howev-
er, we believe that this is the first demonstration that ARNT has
dual co-activator/co-repressor functions in a cell-specific fashion
(Figure 6). In addition, the repercussions of these transcriptional
effects can be observed at the translational and phenotypic levels.
Several models have been hypothesized to explain the molecular
mechanisms underlying transcription factor mediated cross-talk,
particularly the ability of one transcription factor to repress
another’s function [18]. Reugg and colleagues, among others, have
suggested that transcription factor-mediated transrepression might
be the result of competition for a limited pool of co-activator
proteins [27]. However, the identification of ARNT as a co-
repressor in ECC-1 cells unmasks a more complex mechanism of
transrepression at E2-inducible genes then the co-activator
competition model suggests. While these data do not definitively
disprove this model, we believe that our data suggest that it is
unlikely because co-activator competition cannot account for
TCDD-inducible repression in ECC-1 cells as activated AHR
should squelch ARNT’s co-repressor function. In addition, ARNT,
a protein that has demonstrated the ability to recruit numerous co-
activators [12,15,17,41,43,44] should illicit an effect similar to
ligand-activated AHR if co-activator pools were in such limited
supply that competition would hinder individual transcription factor
function. This clearly is not the case in the ECC-1 cell line.
The experimental evidence presented above indicates that AHR
does not require ARNT to mediate its off-target transrepressor
Figure 5. Loss of ARNT promotes cell proliferation in ECC-1 cells and attenuates growth in MCF7 cells. ECC-1 (A) and MCF7 (B) cells
were transfected with either siSCX or siARNT for 6 hours, then trypsinized and reseeded at 10,000 cells/well in 12-well dishes. Twenty-four hours after
seeding, cells were treated with either DMSO or E2 (10 nM) and cell counts were conducted at 0, 48 and 96 hours after treatments with a Fuchs-
Rosenthal Counting Chamber. At the 48 h time point, cells were treated a second time with 10 nM E2. Experiments were done in triplicate and each
trial was counted three times. (C) Western blot analysis of ARNT after siRNA knock-down reveals that significant knock-down was achieved and
persists over a 72 h period. Error bars represent 6 S.D. * p,0.05.
doi:10.1371/journal.pone.0029545.g005
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effects. Loss of ARNT in both MCF7 and ECC-1 cells failed to
abrogate the repressive effects of TCDD on E2-inducible
transcription and protein expression (Figures 2 and 3). The effects
DiMNF-bound AHR are independent of dioxin response element
binding as nuclear extract from cells treated with DiMNF does not
retard the movement of a labeled dioxin response element probe
in gel shift assays [34]. Furthermore, AHR-ARNT dimerization is
a requirement for DNA binding, suggesting that this may not
occur in the presence of DiMNF. This represents a paradigm shift
in our understanding of AHR function and has implications for
the use and effectiveness of selective AHR modulators. Indeed, a
novel AHR antagonist has proven to be a potent stimulator of
AHR-dependent stem cell expansion [45]. Thus, antagonists that
do not elicit AHR-ARNT dimerization might be more effective
repressors of ER function than pure agonists as AHR would not be
squelched by ARNT binding. The SARHM DiMNF is a potent
AHR-dependent repressor of cytokine signaling [33,34]. Further-
more, DiMNF was effective in repressing ER-regulated target gene
expression (Figure 4). Molecular modelling studies demonstrate
that DiMNF forms an extra hydrogen bond with AHR at Thr289
[34], a characteristic not shared with the partial agonist a-
naphthoflavone suggesting that the DiMNF-AHR adopts a unique
confirmation. Thus, the flavonoids represent a class of compounds
that may be attractive targets for further testing and development
to determine their effects on ER target gene expression.
Our experimental evidence demonstrates a TCDD-dependent
repressor function for AHR and a TCDD/AHR-independent co-
activator/co-repressor function for ARNT in estrogen signaling.
These results provide us with further insight into the mechanisms
of transcription factor crosstalk and putative therapeutic targets in
estrogen-positive cancers. Taken together, our data suggest a more
complex mechanism of ARNT function and AHR-mediated
Figure 6. A schematic representation of estrogen signaling, describing the transcriptional functions of ER, AHR and ARNT in ECC-1
and MCF7 cells. The presence of E2 facilitates the assembly of transcriptional modifiers that induce transcription of E2-responsive genes. Ligand
activated AHR represses ER-signaling independent of ARNT. The loss of ARNT in ECC-1 cells, where it acts as a co-repressor, leads to increased
sensitivity to E2 and increased transcriptional activity at ER regulated genes. The loss of ARNT in MCF7 cells, where it acts as a co-activator, leads to
decreased sensitivity to E2 and decreases transcriptional activity at ER regulated genes.
doi:10.1371/journal.pone.0029545.g006
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transrepression of ER-signaling than previously suggested. The
clinical utility of these findings remains to be tested and will be the
subject of future investigations.
Materials and Methods
Materials and Cell culture
39,49-dimethoxy-a-naphthoflavone (DiMNF) was obtained com-
mercially (Indofine Chemical Co., Hillsborough, NJ). ECC-1 and
MCF7 cells (ATCC) were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM; BioWhittaker, Lonza,) with 10% fetal
bovine serum (FBS; HyClone, PerBio, Thermo Fisher Scientific
Inc.) and supplemented with 100 units/ml potassium penicillin-
100 mg/ml streptomycin sulphate (BioWhittaker, Lonza) at 37uC,
20% O2, and 5% CO2. Twenty-four h before any experimental
perturbation, cells were washed 26with PBS, and maintained in
Phenol-Red-free media without FBS [46].
Chromatin immunoprecipitation assays. Chromatin
immunoprecipitation (ChIP) assays were performed as described
by previously [17]. Briefly, cells were plated into 150 cm2 dishes
and serum-starved 24 h before treatment. Treatment of cells was
done in serum-free media supplemented with 3 mg/mL bovine
serum albumin for 45 min. Chromatin complexes were chemically
cross-linked using a 1% formaldehyde/0.7 mol/L HEPES
solution (final concentration), pH 7.8, and complexes were
sonicated to yield DNA fragments of 200 to 900 bp size.
Complexes were precleared with protein A agarose resin
(CalBiochem) and incubated overnight with specific antibodies
[ERa rabbit polyclonal or ARNT goat polyclonal (Santa Cruz)
or AHR rabbit polyclonal described previously [47]. Im-
munoadsorbed complexes were captured on protein A agarose
resin and washed twice with 0.56RIPA, followed by three washes
with 10 mmol/L Tris-HCl (pH 8.0) and 1 mmol/L EDTA.
Samples were eluted off of the resin using 100 mmol/L
NaHCO3 and 1% SDS, and cross-links were reversed at 65uC
overnight. Samples were phenol-chloroform extracted and
precipitated with 70% EtOH and Pellet Paint (Novagen).
Immuno-adsorbed DNA was analyzed by PCR. Primers for the
CYP1A1 enhancer and pS2 promoter have been described
previously [20,48].
Transient transfections
MCF7 and ECC-1 cells were cultured in the conditions
described above until approximately 70% confluent before siRNA
transfection. Cells were transfected with either Green Fluorescence
Protein (GFP) siRNA (Dharmacon), scrambled (SCX) siRNA (DS
Scrambled negative control siRNA, Integrated DNA Technologies
Inc.), AHR siRNAs (Dharmacon) or ARNT siRNAs (Integrated
DNA Technologies Inc., Cat. No. HSC.RNAI.N187426.11.1,
HSC.RNAI.N178426.11.2, HSC.RNAI.N178426.11.3; siARNT
1, siARNT 2, and siARNT 3 respectively). Cells were transfected
with 10–15 nM siRNA using 0.3% (v/v) Trifectin (Integrated
DNA Technologies) according to manufacturer’s protocol. The
cells were allowed to incubate in transfection mix for 6 h at 37uC,
and 5% CO2 after which the transfection mix was removed and
replaced with serum free medium.
Reverse transcription and Real-Time PCR
Reverse transcription and real-time PCR were performed as
described previously [11]. In brief, cells were treated either with
DMSO (Me2SO), TCDD (2 nM), E2 (10 nM), or a combination
of TCDD and E2, for 24 h. For studies involving the selective
AHR modulator 1 mM 39,49-dimethoxy-a-naphthoflavone
(DiMNF) with either DMSO, E2 (10 nM), diMNF (1 mM) or E2
and diMNF in combination. Cells were harvested in TRI Reagent
(Sigma) and total RNA was isolated and subjected to reverse
transcription using a High Capacity cDNA Archive kit (Applied
Biosystems). Complimentary DNA was amplified by real-time
PCR using a Power SYBR Green PCR kit (Applied Biosystems)
according to manufacturer’s protocols. Oligonucleotide pairs used
to amplify human cDNA sequences were described previously
[11]. DNA was amplified for 45 cycles in a StepOne Plus Real-
Time PCR System (Applied Biosystems).
Western blot analysis
In order to determine the effects of TCDD on E2-inducible
protein levels, MCF7 and ECC-1 cells were treated either with
vehicle (Me2SO), TCDD (2 nM), E2 (10 nM), or a combination of
TCDD and E2 for 24 h. For protein analysis that included siRNA
treatment, cells were transfected for 6 h and then starved in serum
free media for 24 h prior to ligand treatments. Cells were
harvested and the protein concentration determined by the RC
DC protein assay (Bio-Rad). Equal amounts of proteins from the
samples were resolved on a SDS-acrylamide gel then transferred to
polyvinylidene fluoride (PVDF) membrane. Upon completion of
transfer, the membrane was wetted with 100% methanol then
probed with anti-ARNT (goat polyclonal IgG; Santa Cruz
Biotechnology, Inc.), anti-AHR (rabbit polyclonal, Biomol,
GmbH), anti-CAT-D (rabbit polyclonal IgG; Santa Cruz
Biotechnology, Inc.), anti-ERa (rabbit polyclonal IgG; Santa Cruz
Biotechnology, Inc.), anti-a-tubulin (mouse monoclonal IgG;
Santa Cruz Biotechnology, Inc.) or anti-XAP2 mouse monoclonal
antibody. The detection was performed using horseradish
peroxidase conjugated anti-mouse or anti-rabbit or anti-goat
IgG and ECL detection kit (GE Healthcare).
Proliferation Assay
MCF7 cells and ECC-1 cells at 75–80% confluency were
transfected with either ARNT or scrambled negative control
siRNA. After 6 h, cells were washed 2 times with PBS, trypsinized
and seeded into 12-well plates at 10,000 cells/well in DMEM with
2.5% charcoal-stripped FBS. Twenty-four hours after plating, E2
was added directly to half the wells to a final concentration of
10 nM. Cells were counted at; 0 (control), 12, 24, 48 and 96 h
following E2 administration. A second treatment of E2 (10 nM)
was added to the cells at 48 hrs. Determinations were performed
in triplicate and each sample was counted three times.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 4.0.
For multiple comparisons (i.e. siRNA experiments) statistical
significance was determined using a 2-way ANOVA with Tukey’s
Multiple Comparison test. Values are presented as means 6
standard error of the mean (SEM). A P value,0.05 was
considered to be significant.
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